A global dental products company that makes the implants, clear aligners, and imaging gear dentists and orthodontists use every day, with brands like Nobel Biocare, Ormco, Kerr, and Spark aligners sold in more than 130 countries. Born in 2019 as a spinoff of Danaher Corporation's dental business, its name combines Latin roots meaning "to be within" and "a view," a nod to looking ahead — and its logo's concentric circles are meant to suggest endless collaborative possibilities.
Envista appoints CEO Paul Keel as Chairman, boosts his pay and grants equity awards.
Paul Keel, President and CEO, was appointed Chairman of the Board effective August 19, 2026, succeeding Scott Huennekens, who remains as Lead Independent Director.
Show detailsHide details
Keel's base salary increased by $200,000 to $1.3 million per year, effective August 24, 2026.
Keel received a one-time equity award of $10 million, comprising $5 million in RSUs and $5 million in PSUs, granted August 18, 2026.
CFO Eric Hammes received a special one-time PSU award valued at $1.5 million, granted August 18, 2026, with performance tied to four-year relative TSR.
The equity awards vest over four years and are subject to forfeiture except in cases of death, early retirement, normal retirement, or qualifying termination within 24 months after a change in control.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 8.01 Other Events · 9.01 Financial Statements and Exhibits
Envista appoints Coree Thomas as Chief Accounting Officer effective August 6, 2026
Thomas joined Envista in February 2023 and previously held controller roles at CBRE Group, Edwards Lifesciences, Exelon, and KPMG.
Show detailsHide details
Faez Kaabi notified Envista of his resignation as Chief Accounting Officer and principal accounting officer, effective August 6, 2026, in connection with his retirement.
Coree Thomas, currently Vice President, Global Controller, will become Vice President and Chief Accounting Officer effective August 6, 2026.
Thomas has no family relationships with company officers or directors and no reportable related transactions.
Kaabi will continue in his role until the effective date to assist with the transition.
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 9.01 Financial Statements and Exhibits
Q4 2025 GAAP net income was $33 million; adjusted EBITDA was $111 million, up 22% year-over-year, with adjusted EBITDA margin of 14.8%.
Show detailsHide details
Q4 2025 sales were $751 million, with core sales growth of 10.8% over Q4 2024.
Q4 2025 GAAP diluted EPS was $0.20; adjusted diluted EPS was $0.38, up 58% year-over-year.
Full-year 2025 sales were $2,719 million, with core sales growth of 6.5%; GAAP net income was $47 million and adjusted EBITDA was $372 million.
For 2026, Envista guides core sales growth of 2% to 4%, adjusted EBITDA growth of 7% to 13%, adjusted diluted EPS of $1.35 to $1.45, and free cash conversion of ~100%.
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits